Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AML
There was bad news and good news in a phase III trial evaluating intensive chemotherapy with or without gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia (AML) patients with newly diagnosed, NPM1-mutated disease. For the primary endpoints of event-free survival (EFS) and overall survival (OS), the gemtuzumab ozogamicin-treated group experienced no benefit, but addition of the […]
Mediterranean diet linked to lower preeclampsia risk
In a new study evaluating the Mediterranean diet and adverse pregnancy outcomes, investigators from the Smidt Heart Institute at Cedars-Sinai found that women who conceived while adhering to the anti-inflammatory diet had a significantly lower risk of developing preeclampsia during pregnancy. The study, published today in the peer-reviewed journal JAMA Network Open, also evaluated the […]
Durable Remissions in CLL With Fixed-Duration Triplet at 4 Years
Four-year follow-up data from a phase II study evaluating obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL) were presented at the American Society of Clinical Oncology annual meeting. In this exclusive MedPage Today video, Kerry Rogers, MD, of the Ohio State University Comprehensive Cancer Center in Columbus, discusses the […]